Literature DB >> 17094576

[Acute lymphoblastic leukemia presenting with calcineurin-inhibitor induced pain syndrome after a second allogeneic bone marrow transplantation].

Shuichiro Takashima1, Akihiko Numata, Toshihiro Miyamoto, Tsuyoshi Shirakawa, Rieko Kinoshita, Kouji Kato, Katsuto Takenaka, Naoki Harada, Koji Nagafuji, Shuichi Taniguchi, Mine Harada.   

Abstract

A 42-year-old woman was referred to us for the treatment of relapsed Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL), which had been maintained in complete remission for seven years after an allogeneic bone marrow transplantation (allo-BMT) from an unrelated donor. She received remission-reinduction chemotherapy combined with imatinib mesylate. After the documentation of the molecular remission of Ph+ALL, she underwent the second allo-BMT from another unrelated donor. GVHD prophylaxis consisted of tacrolimus (TAC) and short-term methotrexate. On day 21, she suddenly suffered from an intermittent severe, cramp-like pain in the right lower limb. The typical pain profile and exclusion of other causative diseases suggested calcineurin-inhibitor induced pain syndrome (CIPS) as a possible cause of pain. The pain was gradually relieved after discontinuation of TAC and administration of several analgesic drugs. CIPS is rarely seen following allogeneic stem cell transplantation (allo-SCT); only three cases have been so far reported to our knowledge. Thus, physicians should be alert to this complication in patients receiving allo-SCT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094576

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  2 in total

Review 1.  Roles of TRESK, a novel two-pore domain K+ channel, in pain pathway and general anesthesia.

Authors:  Dong-Yue Huang; Bu-Wei Yu; Qiu-Wei Fan
Journal:  Neurosci Bull       Date:  2008-06       Impact factor: 5.203

2.  Analysis of five cases of human herpesvirus-6 myelitis among 121 cord blood transplantations.

Authors:  Toshimitsu Ueki; Kenichi Hoshi; Yuki Hiroshima; Masahiko Sumi; Naoaki Ichikawa; Masao Ogata; Takako Satou; Takahiro Fukuda; Hikaru Kobayashi
Journal:  Int J Hematol       Date:  2017-10-11       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.